Company intelligence / Profile preview
GeneVentiv Therapeutics
Raleigh, North Carolina, United Statesgeneventiv.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
GeneVentiv's lead program GENV-HEM (AAV8.FVa) has demonstrated therapeutic efficacy and safety in preclinical studies and received Orphan Drug Designation from the FDA for Hemophilia A and B with or without inhibitors[4]
- Therapeutic areas
- Rare DiseasesHematology
- Modalities
- AAV-based gene therapy
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
ReciBioPharm (for AAV manufacturing)[4]
Beyond the preview
Go deeper on GeneVentiv Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GeneVentiv Therapeutics.